Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1989 Jun;29(2):93–100. doi: 10.1007/BF00199283

Preferential homing of tumor-infiltrating lymphocytes in tumor-bearing mice

Ira H Ames 1,✉, George M Gagne 2, A Mariano Garcia 1, Patricia A John 3, Guido M Scatorchia 1, Russell H Tomar 3, John G McAfee 2
PMCID: PMC11038779  PMID: 2720709

Abstract

In view of the current interest in the use of lymphoid cells in adoptive immunotherapy of patients with advanced cancer, we have studied the homing patterns of various lymphoid effector cells in mammary-tumor-bearing mice. Single-cell suspensions of total splenocytes, natural killer (NK) cells, and lymphokine-activated killer (LAK) cells were prepared from the spleens of C3H/OuJ mice. Tumor-infiltrating lymphocytes (TIL) were isolated from mammary adenocarcinomas excised from retired breeder females of the same substrain. Effector cells were labeled with indium-111 and injected via a tail vein into female C3H/OuJ mice bearing one or more mammary tumors. Twenty-four hours after administration, total splenocytes, NK cells, and LAK cells distributed themselves evenly between normal mammary tissue and mammary adenocarcinomas. Only TIL had a higher concentration in tumors than in corresponding normal mammary tissue. The ability of the different lymphocyte preparations to lyse YAC-1 cells was determined by means of a 4-h 51Cr-release cytotoxicity assay. Cells harvested from LAK cell cultures and further enriched by centrifugation through a discontinuous Percoll gradient and interleukin-2 (IL-2)-stimulated TIL demonstrated the highest levels of cytotoxicity, while total splenocytes and fresh TIL were characterized by the lowest levels. Since IL-2-stimulated TIL were highly cytotoxic and exhibited better tumor localization than both NK cells and LAK cells in this system, they may be the lymphoid effectors of choice for adoptive immunotherapy of advanced cancer.

Keywords: Natural Killer Cell, Adoptive Immunotherapy, Percoll Gradient, Breeder Female, Mammary Adenocarcinoma

References

  • 1.Agah R, Shau H, Mazumder A. Lysosome rich cells contain the lytic activity of lymphokine-activated killer cell populations. Cancer Immunol Immunother. 1987;24:247. doi: 10.1007/BF00205638. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Akporiaye ET, Kudalore M, Stevenson AP, Kraemer PM, Stewart CC. Isolation and reactivity of host effectors associated with the manifestation of concomitant tumor immunity. Cancer Res. 1988;48:1153. [PubMed] [Google Scholar]
  • 3.Allavena P, Merendino A, DiBello M, Pirelli A, Rossini S, Mantovani A. Mechanisms of natural cell-mediated resistance in human solid tumors. Biochim Biophys Acta. 1986;865:281. doi: 10.1016/0304-419x(86)90018-1. [DOI] [PubMed] [Google Scholar]
  • 4.Anderson TM, Ibayashi Y, Holmes EC, Golub SH. Modification of natural killer activity of lymphocytes infiltrating human lung cancers. Cancer Immunol Immunother. 1987;25:65. doi: 10.1007/BF00199303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Anderson TM, Ibayashi Y, Tokuda Y, Colquhoun SD, Holmes EC, Golub SH. Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes. Cancer Res. 1988;48:1180. [PubMed] [Google Scholar]
  • 6.Belldegrun A, Muul LM, Rosenberg SA. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res. 1988;48:206. [PubMed] [Google Scholar]
  • 7.Cikes M, Friberg S, Klein G. Progressive loss of H-2 antigens with concomitant increase of cell-surface antigen(s) determined by Moloney leukemia virus in cultured murine lymphomas. J Natl Cancer Inst. 1973;50:347. doi: 10.1093/jnci/50.2.347. [DOI] [PubMed] [Google Scholar]
  • 8.Cotran RS, Pober JS, Gimbrone MA, Springer TA, Wiebke EA, Gaspari AA, Rosenberg SA, Lotze MT. Endothelial activation during interleukin 2 immunotherapy. J Immunol. 1987;139:1883. [PubMed] [Google Scholar]
  • 9.Ettinghausen SE, Moore JG, White DE, Platanias L, Young NS, Rosenberg SA. Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients. Blood. 1987;69:1654. [PubMed] [Google Scholar]
  • 10.Fujimori Y, Hara H, Nagai K. Effect of lymphokine-activated killer cell fraction on the development of human hematopoietic cells. Cancer Res. 1987;48:534. [PubMed] [Google Scholar]
  • 11.Garcia AM, Gagne GM, Ames IH, Stiteler W, Tomar RH, McAfee JG. Migratory patterns of different indium-111 labeled leukocyte populations (chiefly lymphocytes) from control and thymectomized rats. J Nucl Med. 1988;29:83. [PubMed] [Google Scholar]
  • 12.Grimm EA, Rosenberg SA. The human lymphokine-activated cell phenomenon. Lymphokines. 1984;9:279. [Google Scholar]
  • 13.Honsik CJ, Jung G, Reisfeld RA. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD 2 and GD 3 specifically lyse human tumor cells of neuroectodermal origin. Proc Natl Acad Sci USA. 1986;83:7893. doi: 10.1073/pnas.83.20.7893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Itoh K, Tilden AB, Balch CM. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Cancer Res. 1986;46:3011. [PubMed] [Google Scholar]
  • 15.Julius MH, Simpson E, Herzenberg LA. A rapid method for the isolation of functional thymus-derived murine lymphocytes. Eur J Immunol. 1973;3:645. doi: 10.1002/eji.1830031011. [DOI] [PubMed] [Google Scholar]
  • 16.Kedar E, Weiss DW. The in vitro generation of effector lymphocytes and their employment in tumor immunotherapy. Adv Cancer Res. 1983;38:171. doi: 10.1016/s0065-230x(08)60190-6. [DOI] [PubMed] [Google Scholar]
  • 17.Kimoto Y, Taguchi T. Adoptive immunotherapy of malignant diseases with IL-2-activated lymphocytes. Biken J. 1987;30:29. [PubMed] [Google Scholar]
  • 18.Kradin RL, Boyle LA, Preffer FI, Callahan RJ, Barlai-Kovach M, Strauss HW, Dubinett S, Kurnick JT. Tumorderived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer. Cancer Immunol Immunother. 1987;24:76. doi: 10.1007/BF00199837. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Lafreniere R, Rosenberg SA. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res. 1985;45:3735. [PubMed] [Google Scholar]
  • 20.Lafreniere R, Rosenberg SA. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin-2 (RIL-2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma. J Immunol. 1985;135:4273. [PubMed] [Google Scholar]
  • 21.Lotze MT, Line BR, Mathisen DJ, Rosenberg SA. The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors. J Immunol. 1980;125:1487. [PubMed] [Google Scholar]
  • 22.Lotze MT, Grimm EA, Mazumder A, Strausser JL, Rosenberg SA. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res. 1981;41:4420. [PubMed] [Google Scholar]
  • 23.Loudon WG, Abraham SR, Owen-Schaub LB, Hemingway LL, Hemstreet GP, DeBault LE. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties. Cancer Res. 1988;48:2184. [PubMed] [Google Scholar]
  • 24.Mazumder A, Rosenberg SA. Successful immunotherapy of natural killer resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med. 1984;159:495. doi: 10.1084/jem.159.2.495. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Mazumder A, Eberlein TJ, Grimm EA, Wilson DJ, Keenan AM, Aamodt R, Rosenberg SA. Phase 1 study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells. Cancer. 1984;53:896. doi: 10.1002/1097-0142(19840215)53:4<896::aid-cncr2820530414>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  • 26.Mukherji B, Arnbjarnarson O, Spitznagle LA, Hoffman J, Ergin MT, Spencer RP. Biodistribution of in-111 labeled tumor sensitized autologus lymphocytes in cancer patients. In: Truitt RL, Gale RP, Bortin MM, editors. Cellular immunotherapy of cancer. New York: Alan R. Liss; 1987. p. 325. [PubMed] [Google Scholar]
  • 27.Mule JJ, Shu S, Schwarz SL, Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science. 1984;225:1487. doi: 10.1126/science.6332379. [DOI] [PubMed] [Google Scholar]
  • 28.Muul LM, Spiess PJ, Director EP, Rosenberg SA. Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol. 1987;138:989. [PubMed] [Google Scholar]
  • 29.Nishimura T, Yagi H, Uchiyama Y, Hashimoto Y. Generation of lymphokine-activated killer (LAK) cells from tumor-infiltrating lymphocytes. Cell Immunol. 1986;100:149. doi: 10.1016/0008-8749(86)90015-8. [DOI] [PubMed] [Google Scholar]
  • 30.Ortaldo JR. Cytotoxicity by natural killer cells: Analysis of large granular lymphocytes. Methods Enzymol. 1986;132:445. doi: 10.1016/s0076-6879(86)32030-5. [DOI] [PubMed] [Google Scholar]
  • 31.Owen-Schaub LB, Abraham SR, Hemstreet GP. Phenotypic characterization of murine lymphokine-activated killer cells. Cell Immunol. 1986;103:272. doi: 10.1016/0008-8749(86)90089-4. [DOI] [PubMed] [Google Scholar]
  • 32.Rabinowich H, Cohen R, Bruderman I, Steiner Z, Klajman A. Functional analysis of mononuclear cells infiltrating into tumors: lysis of autologous human tumor cells by cultured infiltrating lymphocytes. Cancer Res. 1987;47:173. [PubMed] [Google Scholar]
  • 33.Reynolds CW, Denn AC, Barlozzari T, Wiltrout RH, Reichardt DA, Herberman RB. Natural killer activity in the rat. IV. Distribution of large granular lymphocytes (LGL) following intravenous and intraperitoneal transfer. Cell Immunol. 1984;86:371. doi: 10.1016/0008-8749(84)90392-7. [DOI] [PubMed] [Google Scholar]
  • 34.Rolstad B, Herberman RB, Reynolds CW. Natural killer cell activity in the rat. V. The circulation patterns and tissue localization of peripheral blood large granular lymphocytes (LGL) J Immunol. 1986;136:2800. [PubMed] [Google Scholar]
  • 35.Rosenberg SA. Adoptive immunotherapy of cancer: accomplishments and prospects. Cancer Treat Rep. 1984;68:233. [PubMed] [Google Scholar]
  • 36.Rosenberg SA. Immunotherapy of cancer by the systemic administration of lymphoid cells plus interleukin-2. J Biol Response Mod. 1984;3:501. [PubMed] [Google Scholar]
  • 37.Rosenberg SA. Immunotherapy of cancer using interleukin 2: current status and future prospects. Immunol Today. 1988;9:58. doi: 10.1016/0167-5699(88)91261-3. [DOI] [PubMed] [Google Scholar]
  • 38.Rosenberg SA, Terry WD. Passive immunotherapy of cancer in animals and man. Adv Cancer Res. 1977;25:323. doi: 10.1016/s0065-230x(08)60637-5. [DOI] [PubMed] [Google Scholar]
  • 39.Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233:1318. doi: 10.1126/science.3489291. [DOI] [PubMed] [Google Scholar]
  • 40.Silvennoinen O, Hurme M. Simultaneous development of cells with large granular lymphocyte (LGL) morphology and natural killer (NK) cell lytic activity after bone marrow (BM) transplantation in mice. Immunology. 1988;63:105. [PMC free article] [PubMed] [Google Scholar]
  • 41.Takai N, Tanaka R, Yoshida S, Hara N, Saito T. In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells. Cancer Res. 1988;48:2047. [PubMed] [Google Scholar]
  • 42.Topalian SL, Solomon D, Avis FP, Chang AE, Freerksen DL, Linehan WM, Lotze MT, Robertson CN, Seipp CA, Simon P, Simpson CG, Rosenberg SA. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol. 1988;6:839. doi: 10.1200/JCO.1988.6.5.839. [DOI] [PubMed] [Google Scholar]
  • 43.von Kleist S, Berling J, Bohle W, Wittekind C. Immunohistological analysis of lymphocyte subpopulations infiltrating breast carcinomas and benign lesions. Int J Cancer. 1987;40:18. doi: 10.1002/ijc.2910400105. [DOI] [PubMed] [Google Scholar]
  • 44.Wei W-Z, Heppner G. Natural killer activity of lymphocytic infiltrates in mouse mammary lesions. Br J Cancer. 1987;55:589. doi: 10.1038/bjc.1987.120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Wei W-Z, Malone K, Mahoney K, Heppner G. Characterization of lymphocytic infiltrates in normal, preneoplastic, and neoplastic mouse mammary tissues. Cancer Res. 1986;46:2680. [PubMed] [Google Scholar]
  • 46.West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK. Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987;316:898. doi: 10.1056/NEJM198704093161502. [DOI] [PubMed] [Google Scholar]
  • 47.Whiteside TL, Miescher S, Hurlimann J, Moretta L, von Fliedner V. Clonal analysis and in situ characterization of lymphocytes infiltrating human breast carcinomas. Cancer Immunol Immunother. 1986;23:169. doi: 10.1007/BF00205646. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Yamaki T, Uede T, Shijubo N, Kikuchi K. Functional analysis of mononuclear cells infiltrating into tumors. III. Soluble factors involved in the regulation of T lymphocyte infiltration into tumors. J Immunol. 1988;140:4388. [PubMed] [Google Scholar]
  • 49.Yron I, Wood TA, Spiess PJ, Rosenberg SA. In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors. J Immunol. 1980;125:238. [PubMed] [Google Scholar]
  • 50.Zarcone D, Prasthofer EF, Malavasi F, Pistoia V, LoBuglio AF, Grossi CE. Ultrastructural analysis of human natural killer cell activation. Blood. 1987;69:1725. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES